STOCK TITAN
  1. Home
  2. News
  3. CHRS

Coherus Biosciences Inc - CHRS STOCK NEWS

Welcome to our dedicated news page for Coherus Biosciences (Ticker: CHRS), a resource for investors and traders seeking the latest updates and insights on Coherus Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Coherus Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Coherus Biosciences's position in the market.

News
Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Coherus BioSciences, Inc. (Nasdaq: CHRS) to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.82%
Tags
conferences
-
News
Coherus Announces U.S. Launch of LOQTORZI™
Rhea-AI Summary
Coherus BioSciences, Inc. (CHRS) launches LOQTORZI, the first and only FDA-approved treatment for NPC in all lines of therapy. LOQTORZI is indicated in combination with chemotherapy for 1st line treatment and as monotherapy for patients with disease progression on or after platinum containing chemotherapy, irrespective of PD-L1 status. The drug is now available for purchase through select specialty distributors in the United States. LOQTORZI has demonstrated impressive clinical benefits, including progression-free survival (PFS) and overall survival (OS), offering new hope for extended survival to patients with recurrent or metastatic nasopharyngeal carcinoma (NPC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.71%
Tags
none
-
News
Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
Rhea-AI Summary
Coherus BioSciences, Inc. (Nasdaq: CHRS) announced FDA approval of UDENYCA ONBODY, an on-body injector for pegfilgrastim, with a unique retractable needle mechanism and five-minute delivery time. The device is designed to maximize safety and comfort for cancer patients receiving pegfilgrastim, offering a novel administration option for patients and physicians.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.39%
Tags
fda approval
News
Coherus BioSciences Announces New Employment Inducement Grants
Rhea-AI Summary
Coherus BioSciences, Inc. (Nasdaq: CHRS) granted options to purchase 192,000 shares of common stock to five newly hired employees. One executive was granted an option to purchase 150,000 shares, and four non-officer employees were granted options to purchase 42,000 shares. The options were granted under the 2016 Employment Commencement Incentive Plan approved by the Company's board of directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx
Rhea-AI Summary
Coherus BioSciences, ticker symbol CHRS, announced that LOQTORZI is recommended as the only Preferred Category 1 treatment option in first-line treatment for adults with metastatic or recurrent locally advanced NPC in combination with chemotherapy, and as the only preferred regimen in subsequent lines of therapy. LOQTORZI is the first and only FDA-approved treatment for recurrent or metastatic NPC in all lines of therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.95%
Tags
none
-
News
Coherus BioSciences Announces CFO Transition Plans
Rhea-AI Summary
Coherus BioSciences, Inc. (CHRS) announced the resignation of Chief Financial Officer McDavid Stilwell, with his last day of employment set for December 31, 2023. The company will appoint an interim Principal Financial Officer while searching for a new CFO. Coherus aims to achieve its 2024 goals and beyond, with a focus on new product launches and immuno-oncology pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.48%
Tags
none
News
Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress
Rhea-AI Summary
Coherus BioSciences, Inc. (CHRS) announced positive data from the ongoing Phase 1b/2 clinical trial of casdozokitug (casdozo), a first-in-class IL-27-targeting antibody, being presented at the 2023 ESMO Immuno-Oncology Congress. The data supports continued evaluation of casdozo in combination with anti-PD-1 antibody treatments, including ongoing Phase 2 cohort of casdozo with toripalimab in treatment refractory NSCLC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.09%
Tags
clinical trial
-
News
Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association
Rhea-AI Summary
Coherus Biosciences, Inc. (CHRS) and Shanghai Junshi Biosciences Co., Ltd (1877, 688180) announced the publication of the final overall survival results from the pivotal JUPITER-02 study, revealing a 37% reduction in the risk of death in NPC patients treated with toripalimab plus chemotherapy versus chemotherapy alone. LOQTORZI is the first FDA-approved treatment for recurrent or metastatic NPC in all lines of therapy and will be available to NPC patients in the U.S. in January 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.76%
Tags
clinical trial
-
News
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
Rhea-AI Summary
Coherus BioSciences reported a 27% increase in net revenue to $74.6 million for the quarter ended September 30, 2023. CIMERLI® net sales rose 50% to $40 million, while UDENYCA® net sales increased to $33 million. The FDA approved LOQTORZI™ for the treatment of nasopharygeal carcinoma, with a commercial launch planned for Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.23%
Tags
earnings
News
Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)
Rhea-AI Summary
Coherus BioSciences presents data from three immuno-oncology pipeline programs at the 38th Annual Meeting of SITC. The data support the development of their anti-IL-27 antibody casdozokitug, anti-CCR8 antibody CHS-114, and anti-PD-1 antibody LOQTORZI™. The data demonstrate distinct IL-27-mediated gene expression, the role of CCR8+ Tregs in the tumor microenvironment, and the enhanced clinical efficacy of LOQTORZI™ in combination with chemotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.73%
Tags
none
Stock CHRS logo
Coherus Biosciences Inc

Nasdaq:CHRS

CHRS Rankings

#3590 Ranked by Market Cap
#5124 Ranked by Stock Gains
N/A Ranked by Dividends

CHRS Stock Data

251.35M
103.90M
1.35%
77.99%
20.8%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Redwood City

About CHRS

coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp